Nautilus Biotechnology Inc expected to post a loss of 17 cents a share - Earnings Preview

Nautilus Biotechnology

28/04/2023 17:49

* Nautilus Biotechnology Inc  NAUT.OQ   NAUT.O  is expected
to show no change in quarterly revenue when it reports 
results on May 2. 
    * 
    * ​Refinitiv's mean analyst estimate for Nautilus
Biotechnology
Inc is for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nautilus
Biotechnology Inc is $6​, above​ its last closing price
of $2.54. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.14       -0.15      -0.11     Beat    28.3
 Sep. 30 2022  -0.15       -0.15      -0.11     Beat    25.4
 Jun. 30 2022  -0.17       -0.17      -0.12     Beat    28.4​
 Mar. 31 2022  -0.16       -0.16      -0.13     Beat    17
 ​​Dec.        -0.14       -0.13      -0.13     Met     1.9
 31 2021                                                
 Sep. 30 2021  -0.10       -0.10      -0.12     Missed  -20​
 Jun. 30 2021  -0.07       -0.07      -0.19     Missed  -171.4
 This summary was machine generated April 28 at 16:49 GMT.  All
figures in US dollars  unless otherwise stated